patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_999587 | REC_0005601 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 5.5 | 75 | male | 2 | 7 | 5.4 | 1 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:58.231131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969738 | REC_0005602 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 6.8 | 77 | female | 1 | 44 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.231359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203147 | REC_0005603 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.1 | 71 | female | 1 | 27 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.231586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947660 | REC_0005604 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.3 | 73 | female | 1 | 39 | 5 | 2 | pembrolizumab 200 mg q3w | 16.9 | true | MSS | 2026-03-15T05:35:58.231861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537667 | REC_0005605 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 15.9 | 74 | male | 1 | 6 | 7 | 5 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:35:58.232220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950965 | REC_0005606 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 9.8 | 81 | female | 2 | 16 | 6.6 | 7 | pembrolizumab 200 mg q3w | 6.3 | false | MSS | 2026-03-15T05:35:58.232464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562412 | REC_0005607 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 4.6 | 49 | male | 0 | 20 | 5.8 | 5 | entrectinib 600 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:58.232700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736923 | REC_0005608 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.4 | 58 | male | 1 | 2 | 5.3 | 4 | osimertinib 80 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:35:58.232936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720182 | REC_0005609 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 24 | 10.1 | 81 | female | 1 | 7 | 6.3 | 0 | pembrolizumab 200 mg q3w | 39.1 | false | MSS | 2026-03-15T05:35:58.233169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529958 | REC_0005610 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.7 | 63 | male | 0 | 40 | 5.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:35:58.233403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875057 | REC_0005611 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.6 | 68 | male | 1 | 17 | 3.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:58.233637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349093 | REC_0005612 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8 | 90 | female | 0 | 47 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.1 | false | MSS | 2026-03-15T05:35:58.233863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306343 | REC_0005613 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.2 | 69 | male | 0 | 36 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:58.234095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305977 | REC_0005614 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.1 | 70 | female | 2 | 33 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.234322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159323 | REC_0005615 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.8 | 69 | female | 0 | 26 | 3.5 | 7 | sotorasib 960 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.234556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363248 | REC_0005616 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 17.7 | 68 | female | 0 | 25 | 6.2 | 5 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.234785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397562 | REC_0005617 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.5 | 65 | male | 0 | 58 | 5.6 | 7 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:35:58.235070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402747 | REC_0005618 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 68 | female | 0 | 6 | 4.2 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:58.235308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734542 | REC_0005619 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.4 | 67 | male | 0 | 10 | 4.5 | 4 | alectinib 600 mg BID | 10.2 | true | MSS | 2026-03-15T05:35:58.235545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246415 | REC_0005620 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.9 | 65 | male | 1 | 17 | 5.3 | 2 | pembrolizumab 200 mg q3w | 22.8 | true | MSS | 2026-03-15T05:35:58.235776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191748 | REC_0005621 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.9 | 60 | male | 0 | 15 | 5.8 | 1 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.236013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997611 | REC_0005622 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 6.8 | 72 | female | 2 | 29 | 5.5 | 5 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:58.236327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639042 | REC_0005623 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 6 | 68 | female | 1 | 19 | 6 | 1 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:35:58.236562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547767 | REC_0005624 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.9 | 58 | female | 1 | 40 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.6 | true | MSS | 2026-03-15T05:35:58.236795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665034 | REC_0005625 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.8 | 50 | male | 0 | 16 | 6.8 | 2 | sotorasib 960 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:58.237029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571860 | REC_0005626 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.8 | 69 | female | 0 | 11 | 6.3 | 3 | pembrolizumab 200 mg q3w | 16.6 | false | MSS | 2026-03-15T05:35:58.237265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201970 | REC_0005627 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 8.5 | 70 | female | 1 | 15 | 5.7 | 1 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:58.237497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865827 | REC_0005628 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 13.7 | 74 | female | 1 | 17 | 5.8 | 0 | alectinib 600 mg BID | 38.2 | false | MSS | 2026-03-15T05:35:58.237727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539476 | REC_0005629 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 9 | 65 | female | 1 | 24 | 4.2 | 2 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:58.237960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873715 | REC_0005630 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 3.9 | 90 | female | 1 | 13 | 6.2 | 8 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:35:58.238240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424437 | REC_0005631 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.6 | 77 | female | 1 | 51 | 6.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:35:58.238475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225207 | REC_0005632 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.7 | 73 | male | 2 | 36 | 6.3 | 1 | pembrolizumab 200 mg q3w | 20.9 | true | MSS | 2026-03-15T05:35:58.238708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364571 | REC_0005633 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 12.8 | 63 | female | 0 | 17 | 5 | 2 | sotorasib 960 mg daily | 20.4 | true | MSS | 2026-03-15T05:35:58.238949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352329 | REC_0005634 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.2 | 61 | male | 0 | 59 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:58.239180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596370 | REC_0005635 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11 | 75 | female | 2 | 11 | 2.9 | 5 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:35:58.239411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519885 | REC_0005636 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 4.6 | 67 | female | 0 | 33 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:58.239642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147968 | REC_0005637 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 19.4 | 66 | female | 0 | 16 | 4.7 | 5 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:58.239874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726157 | REC_0005638 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.8 | 70 | male | 2 | 21 | 4.3 | 5 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:58.240139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662565 | REC_0005639 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 14.5 | 67 | male | 1 | 5 | 5.2 | 2 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:58.240380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697151 | REC_0005640 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 17.7 | 69 | female | 1 | 19 | 4.7 | 2 | osimertinib 80 mg daily | 27.4 | true | MSI-H | 2026-03-15T05:35:58.240612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557055 | REC_0005641 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 4.5 | 62 | female | 1 | 34 | 4.5 | 6 | sotorasib 960 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:58.240845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784954 | REC_0005642 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.3 | 68 | female | 1 | 13 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:58.241073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176861 | REC_0005643 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.5 | 74 | female | 1 | 11 | 6.6 | 2 | pembrolizumab 200 mg q3w | 19.4 | false | MSS | 2026-03-15T05:35:58.241349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295054 | REC_0005644 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 3.4 | 73 | female | 2 | 20 | 4.7 | 1 | alectinib 600 mg BID | 27.4 | false | MSS | 2026-03-15T05:35:58.241586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699845 | REC_0005645 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.6 | 63 | male | 0 | 37 | 2 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:58.241820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474584 | REC_0005646 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 15.3 | 69 | female | 0 | 12 | 4.7 | 1 | pembrolizumab 200 mg q3w | 20.7 | false | MSI-H | 2026-03-15T05:35:58.242053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184022 | REC_0005647 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 8.2 | 66 | female | 0 | 15 | 5.9 | 1 | alectinib 600 mg BID | 21.8 | true | MSS | 2026-03-15T05:35:58.242283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891058 | REC_0005648 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 10.4 | 54 | female | 0 | 18 | 5.4 | 6 | alectinib 600 mg BID | 9.9 | false | MSS | 2026-03-15T05:35:58.242516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940412 | REC_0005649 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 6.7 | 80 | female | 1 | 14 | 5.6 | 2 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:58.242743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759407 | REC_0005650 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 7 | 74 | female | 1 | 15 | 5.7 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.242971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685224 | REC_0005651 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 10.2 | 72 | female | 2 | 14 | 4.5 | 6 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:58.243201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259420 | REC_0005652 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.5 | 77 | female | 2 | 20 | 4 | 4 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:58.243433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764524 | REC_0005653 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 13.7 | 50 | male | 0 | 22 | 6.5 | 7 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.243669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829434 | REC_0005654 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.6 | 62 | male | 0 | 10 | 5.5 | 2 | osimertinib 80 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:35:58.243906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272023 | REC_0005655 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 37 | 3.5 | 63 | female | 0 | 22 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:58.244187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845686 | REC_0005656 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 3.7 | 74 | female | 1 | 21 | 3.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:58.244465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156668 | REC_0005657 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.8 | 67 | female | 0 | 11 | 4.8 | 2 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:58.244708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620591 | REC_0005658 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 17.4 | 70 | female | 1 | 16 | 5.4 | 9 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:58.244941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886263 | REC_0005659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 5.5 | 58 | male | 1 | 21 | 5.5 | 6 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.245187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223420 | REC_0005660 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.1 | 82 | female | 3 | 38 | 6.7 | 6 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:35:58.245416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179175 | REC_0005661 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.1 | 66 | female | 1 | 41 | 6.9 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.245646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139423 | REC_0005662 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 10.5 | 62 | male | 0 | 5 | 4.7 | 1 | entrectinib 600 mg daily | 27 | true | MSI-H | 2026-03-15T05:35:58.245881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203061 | REC_0005663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10 | 70 | female | 1 | 24 | 3.1 | 4 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:58.246117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218388 | REC_0005664 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.3 | 71 | male | 1 | 18 | 3.5 | 2 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:58.246349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381886 | REC_0005665 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 15.2 | 69 | male | 0 | 16 | 6.1 | 1 | pembrolizumab 200 mg q3w | 15.3 | false | MSS | 2026-03-15T05:35:58.246586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610993 | REC_0005666 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.6 | 55 | male | 0 | 16 | 5.4 | 3 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.246819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306078 | REC_0005667 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.1 | 64 | male | 1 | 62 | 5.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:58.247048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676537 | REC_0005668 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 9.2 | 59 | male | 0 | 12 | 7.1 | 6 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.247280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380868 | REC_0005669 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.1 | 53 | male | 0 | 28 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 20 | false | MSS | 2026-03-15T05:35:58.247562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131496 | REC_0005670 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.6 | 60 | male | 1 | 77 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:35:58.247797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615633 | REC_0005671 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.1 | 58 | female | 1 | 18 | 5.2 | 6 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.248034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940347 | REC_0005672 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.5 | 68 | female | 1 | 18 | 5.9 | 5 | alectinib 600 mg BID | 18.2 | false | MSS | 2026-03-15T05:35:58.248295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246144 | REC_0005673 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 4.9 | 69 | female | 1 | 17 | 5.9 | 8 | osimertinib 80 mg daily | 13.5 | true | MSS | 2026-03-15T05:35:58.248531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408711 | REC_0005674 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.9 | 69 | female | 0 | 8 | 4.8 | 4 | alectinib 600 mg BID | 6 | true | MSS | 2026-03-15T05:35:58.248763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494117 | REC_0005675 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 3.9 | 51 | female | 0 | 21 | 5.9 | 4 | sotorasib 960 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.248993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316338 | REC_0005676 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 17.4 | 59 | female | 1 | 8 | 5.5 | 4 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:58.249228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558149 | REC_0005677 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.6 | 75 | male | 0 | 66 | 5.4 | 6 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:35:58.249536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252652 | REC_0005678 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 13.4 | 77 | female | 2 | 7 | 5.2 | 5 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.249776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405346 | REC_0005679 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 11.8 | 67 | female | 0 | 9 | 4.8 | 2 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:58.250009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923688 | REC_0005680 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.1 | 66 | female | 0 | 19 | 6 | 5 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:58.250237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473631 | REC_0005681 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9 | 78 | female | 2 | 9 | 5.4 | 5 | alectinib 600 mg BID | 18.4 | true | MSS | 2026-03-15T05:35:58.250463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820442 | REC_0005682 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.6 | 53 | male | 0 | 13 | 6.4 | 1 | entrectinib 600 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:58.250744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319137 | REC_0005683 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 37 | 5.7 | 90 | female | 3 | 62 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:58.250981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603271 | REC_0005684 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.8 | 64 | female | 0 | 58 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:58.251214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831729 | REC_0005685 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.8 | 69 | female | 1 | 11 | 5.4 | 5 | alectinib 600 mg BID | 10.8 | true | MSI-H | 2026-03-15T05:35:58.251448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583608 | REC_0005686 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.3 | 76 | female | 1 | 14 | 5.6 | 4 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:58.251679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535227 | REC_0005687 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 19 | 45 | male | 0 | 16 | 3.8 | 1 | alectinib 600 mg BID | 20 | false | MSI-H | 2026-03-15T05:35:58.251916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713866 | REC_0005688 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 19 | 73 | male | 2 | 11 | 5.1 | 4 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:58.252175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928656 | REC_0005689 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 15.6 | 73 | female | 1 | 19 | 8.9 | 1 | sotorasib 960 mg daily | 24.7 | false | MSI-H | 2026-03-15T05:35:58.252409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779658 | REC_0005690 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 24 | 4.6 | 66 | female | 0 | 17 | 5.9 | 0 | pembrolizumab 200 mg q3w | 40.8 | true | MSS | 2026-03-15T05:35:58.252639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352943 | REC_0005691 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 12 | 54 | female | 0 | 14 | 6.5 | 1 | osimertinib 80 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:58.252873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887816 | REC_0005692 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 7.9 | 66 | female | 1 | 21 | 7.9 | 7 | pembrolizumab 200 mg q3w | 20.1 | true | MSS | 2026-03-15T05:35:58.253099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441896 | REC_0005693 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 15.7 | 50 | male | 0 | 11 | 6.3 | 5 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:58.253331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955912 | REC_0005694 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.3 | 64 | male | 1 | 58 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:58.253561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840784 | REC_0005695 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 2.7 | 68 | female | 1 | 12 | 5 | 9 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.253838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344518 | REC_0005696 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 38 | 4.3 | 67 | female | 1 | 71 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:58.254067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353978 | REC_0005697 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.8 | 70 | male | 2 | 12 | 5 | 1 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.254301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163440 | REC_0005698 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.6 | 72 | female | 1 | 18 | 5.9 | 5 | entrectinib 600 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:58.254533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894131 | REC_0005699 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 8.1 | 52 | male | 0 | 17 | 3.8 | 0 | entrectinib 600 mg daily | 69.4 | false | MSS | 2026-03-15T05:35:58.254765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709070 | REC_0005700 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.9 | 74 | female | 2 | 12 | 5.8 | 2 | alectinib 600 mg BID | 4.1 | false | MSI-H | 2026-03-15T05:35:58.254999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.